多机构甲状腺髓样癌协作登记:罕见肿瘤登记能否准确代表真实世界患者人群?
本研究比较了1995至2018年间纳入甲状腺髓样癌协作登记(MTCCoRe)的1416例患者与德克萨斯癌症登记(TCR)、加州癌症登记(CCR)及监测、流行病学和最终结果(SEER)登记患者的 demographics 与临床特征。结果显示MTCCoRe患者更年轻、T3-4和N1比例更高、接受全身治疗比例更高,但西班牙裔和黑人患者比例较低。作者建议未来登记和临床试验应通过社区参与等方式有意纳入代表性不足的群体。
要点
- MTCCoRe中20-54岁患者占58.0%,高于TCR的50.2%、CCR的47.2%和SEER的44.8%(p<0.0001)。
- MTCCoRe中T3-4占28.6%、N1占49.4%,高于TCR(12.7%、32.2%)、CCR(18.6%、32.4%)和SEER(24%、37.8%)(p<0.0001)。
- MTCCoRe中西班牙裔和黑人患者比例分别为10.1%和3.8%,低于TCR(23.7%、8.2%)、CCR(24.8%、4.9%)和SEER(15.9%、8.2%)(p<0.001)。
核心结论
- 多机构登记中甲状腺髓样癌患者的临床人口学特征与基于人群的数据库不同,西班牙裔和黑人患者比例较低,但增加了治疗方式的数据。
- 未来MTCCoRe及其他登记和临床试验的入组工作应通过社区参与、患者利益相关者参与以及提供非英语研究材料等方式有意纳入代表性不足的群体,以产生更具普遍性的结果和结论。
研究设计与样本
- 比较1995年至2018年间纳入MTCCoRe、德克萨斯癌症登记(TCR)、加州癌症登记(CCR)和SEER的甲状腺髓样癌患者的人口学和临床特征。
- MTCCoRe共识别1416例患者,TCR 329例,CCR 2105例,SEER 3820例。
主要发现
- 20-54岁患者比例:MTCCoRe 58.0%,TCR 50.2%,CCR 47.2%,SEER 44.8%(p<0.0001)。
- 女性比例:MTCCoRe 55.9%,TCR 61.4%,CCR 59%,SEER 57.5%(p=0.3)。
- 西班牙裔和黑人患者比例:MTCCoRe 10.1%和3.8%,TCR 23.7%和8.2%,CCR 24.8%和4.9%,SEER 15.9%和8.2%(p<0.001)。
- T3-4和N1比例:MTCCoRe 28.6%和49.4%,TCR 12.7%和32.2%,CCR 18.6%和32.4%,SEER 24%和37.8%(p<0.0001)。
- M1疾病患病率:MTCCoRe 10%,TCR 11.9%,CCR 14.1%,SEER 9.5%(p<0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Large population-based registries, such as the Surveillance, Epidemiology and End Results (SEER) Registry, help in the study of rare tumors, including medullary thyroid cancer (MTC), but lack data to understand the natural history of the disease. The Medullary Thyroid Cancer Collaborative Registry (MTCCoRe) is an exhaustive multi-institutional collection of demographic, clinical, and pathological data. To determine the extent to which MTCCoRe represents the real-world MTC population, we compared the characteristics of patients enrolled in MTCCoRe with patients enrolled in population-based cancer registries. Methods: Comparison of demographic and clinical characteristics of MTC patients who were enrolled in MTCCoRe, Texas Cancer Registry (TCR), California Cancer Registry (CCR), and SEER between 1995 and 2018. Results: A total of 1416 patients were identified in MTCCoRe, 329 in TCR, 2105 in CCR, and 3820 in SEER. Percentages of patients 20-54 years in MTCCoRe were 58.0%, 50.2% in TCR, 47.2% in CCR, and 44.8% in SEER (p < 0.0001). About half of the patients were female (55.9% in MTCCoRe, 61.4% in TCR, 59% in CCR, and 57.5% in SEER (p = 0.3). Percentages of Hispanic and Black patients differed among cohorts (10.1% and 3.8% for MTCCoRe, 23.7% and 8.2% for TCR, 24.8% and 4.9% in CCR, and 15.9% and 8.2% for SEER, respectively; p < 0.001). MTCCoRe patients presented with more advanced T and N classifications than patients in the other registries (MTCCoRe, 28.6% T3-4 and 49.4% N1; TCR, 12.7% and 32.2%; CCR, 18.6% and 32.4%; and SEER, 24% and 37.8%; p < 0.0001). Prevalence of M1 disease was 10% in MTCCoRe, 11.9% in TCR, 14.1% in CCR, and 9.5% in SEER (p < 0.0001). In the MTCCoRe, 11.4% underwent systemic therapy (compared with 0.3% in TCR and 5.6% in CCR). Conclusions: The clinicodemographic profile of patients with MTC enrolled in a multi-institutional registry differs from those enrolled in population-based databases, with lower proportions of Hispanic and Black patients but additive data on treatment modalities. Moving forward, MTCCoRe and other registry and clinical trial enrollment efforts should intentionally include underrepresented groups via community engagement techniques, patient stakeholder involvement, and inclusion of languages other than English in study materials to yield more generalizable results and conclusions.
引用
- Szabo Yamashita T, Williams-Perez SM, Ehsan S, et al. The Multi-Institutional Medullary Thyroid Cancer Collaborative Registry: Can a Rare Tumor Registry Accurately Represent the Real-World Patient Population? Thyroid. 2024. PMID: 38984944. doi:10.1089/thy.2024.0239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。